Compare BHR & ACOG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | BHR | ACOG |
|---|---|---|
| Founded | 2013 | 2000 |
| Country | United States | Canada |
| Employees | N/A | 71 |
| Industry | Real Estate Investment Trusts | |
| Sector | Real Estate | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 159.3M | 185.1M |
| IPO Year | N/A | N/A |
| Metric | BHR | ACOG |
|---|---|---|
| Price | $2.16 | $8.13 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $16.00 |
| AVG Volume (30 Days) | ★ 702.4K | 92.2K |
| Earning Date | 05-06-2026 | 05-14-2026 |
| Dividend Yield | ★ 8.47% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $139.22 |
| Revenue Next Year | N/A | $134.48 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.88 | $4.50 |
| 52 Week High | $3.19 | $10.14 |
| Indicator | BHR | ACOG |
|---|---|---|
| Relative Strength Index (RSI) | 52.16 | 62.00 |
| Support Level | $1.93 | $5.17 |
| Resistance Level | $2.61 | $8.80 |
| Average True Range (ATR) | 0.09 | 0.54 |
| MACD | 0.02 | -0.07 |
| Stochastic Oscillator | 74.07 | 57.78 |
Braemar Hotels & Resorts Inc is a real estate investment trust company that invests in high revenue per available room, or RevPAR, luxury hotels and resorts. The firm operates in various U.S. states such as California, Texas, Washington, Philadelphia, Florida, and Illinois as well as Washington, D.C. and St. Thomas, U.S. Virgin Islands. The company operates through its direct hotel investment segment of the hotel lodging industry. Its revenue streams include rooms, food and beverage, and other. The firm's hotels operate under various brands, such as Marriott, Hilton, Courtyard, and, among others.
Alpha Cognition Inc is a biopharmaceutical company dedicated to developing treatments for patients suffering from neurodegenerative diseases, such as Alzheimers disease, for which there are limited or no treatment options. The Companies current focus is on the commercial manufacturing and sales of ZUNVEYL oral tablet formulation. The Companies commercial development program for ZUNVEYL is focused on building a long-term care commercial team that can focus on providing key points of differentiation, exploiting key issues with existing Acetylcholinesterase inhibitors treatments, and seeking potential licensing partners for other additional indications and new formulations.